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Endolymphatic potentialThe neuraminidase-1 (Neu1) knockout mouse model is a phenocopy of the lysosomal storage disease (LSD)
sialidosis, characterized by multisystemic and neuropathic symptoms, including hearing loss. We have
characterized the auditory defects in Neu1−/− mice and found that hearing loss involves both conductive
and sensorineural components. Auditory brainstem response (ABR) thresholds were signiﬁcantly elevated in
Neu1−/− mice at P21 (48 –55 dB), and hearing loss appeared progressive (53 –66 dB at P60). At these ages
Neu1−/− mice accumulated cerumen in the external ear canal and had a thickened mucosa and
inﬂammation in the middle ear. In cochleae of adult wild-type mice, Neu1 was expressed in several cell
types in the stria vascularis, the organ of Corti, and spiral ganglion. Progressive morphological abnormalities
such as extensive vacuolization were detected in the Neu1−/− cochleae as early as P9. These early
morphologic changes in Neu1−/− cochleae were associated with oversialylation of several lysosomal
associated membrane proteins (Lamps) in the stria vascularis. A marked increase in the expression and
apical localization of Lamp-1 in marginal cells of the stria vascularis predicts exacerbation of lysosomal
exocytosis into the endolymph. Consequently, the endolymphatic potential in Neu1−/−mice was reduced by
approximately 20 mV at ages P31–P44, which would cause dysfunction of transduction in sensory hair cells.
This study suggests a molecular mechanism that contributes to hearing loss in sialidosis and identiﬁes
potential therapeutic targets.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Neuraminidase-1 (NEU1) initiates the intralysosomal hydrolysis of
sialo-oligosaccharides, glycolipids, and glycoproteins by removing
their terminal sialic acid residues. In human andmurine tissues, NEU1
forms a high molecular weight complex (N1000 kDa) with at least 2
other proteins—β-galactosidase (β-gal) and the protective protein
cathepsin A (PPCA) [1]. In lysosomes, NEU1 and β-gal are dependent
on PPCA for the acquisition of catalytic activity and to maintain a
stable conformation. Whereas NEU1 activity is exclusively present in
the high molecular weight complex, PPCA and β-gal activities are also
present in a lower molecular weight complex (∼700 kDa) and as free
forms [2].262 Danny Thomas Place ms
1; fax: +1 901 595 2270. A.
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ll rights reserved.Deﬁciency of NEU1 is associated with 2 neurodegenerative auto-
somal recessive lysosomal storage diseases (LSDs): sialidosis, caused
by structural lesions in the lysosomal NEU1 locus on chromosome
6p21 [3], and galactosialidosis (GS), a combined deﬁciency of NEU1
and β-gal caused by mutations in the PPCA gene on chromosome
20q13.1 [1]. Patients with sialidosis are characterized by multiple
phenotypes, which are classiﬁed according to the age of onset and
severity of symptoms, and usually correlate with the level of residual
enzyme activity [4]. Type I sialidosis (or cherry-red spot/myoclonus
syndrome) is an attenuated form of the disease that has an onset in
the second decade of life and is associated with progressive vision
loss, hearing loss, nystagmus, ataxia, and grand mal seizures [3].
Type II sialidosis, a severe form of the disease, is subdivided into 3
groups: congenital or hydropic (in utero), infantile (onset within
ﬁrst year of life), and juvenile (onset in ﬁrst or second decade of life)
[3]. The congenital form is associated with either hydrops fetalis and
stillbirth or neonatal ascites and death at an early age [3]. Type II
sialidosis may also be associated with symptoms such as facial
edema, inguinal hernias, hepatosplenomegaly, and stippling of the
epiphyses. Patients with Type II sialidosis patients who survive
Fig. 1. ABR threshold elevation (dB SPL) in Neu1−/− mice at ages P21 and P60. Click
ABR results were plotted in (A). Neu1−/− mice show a threshold elevation of 55 dB
SPL (⁎⁎Pb0.001 compared to P21 Neu1+/+ mice, Student’s t-test) as early as P21 and
66 dB SPL at P60 (&&Pb0.001 compared to P60 Neu1+/+ mice, Student's t-test). No
signiﬁcant difference was found between P21 Neu1+/+ mice and P60 Neu1+/+ mice
(P=0.87, Student's t-test) whereas the threshold elevation in P60 Neu1−/− mice
was signiﬁcantly higher than that of P21 Neu1−/− mice (#Pb0.05 compared to P21
Neu1−/− mice, Student's t-test) (B) The ABR results from 8, 16, and 32 kHz tone
stimuli are consistent with the click ABR results; Neu1−/− mice show a signiﬁcant
threshold elevation at both P21 (Pb0.05, two-way ANOVA) and P60 (Pb0.001, two-
way ANOVA) compared to the control littermates. 4 Neu1+/+ mice and 4 Neu1−/−
mice were used at P21. 4 Neu1+/+ mice and 6 Neu1−/− mice were used at P60.
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which includes coarse facies, visceromegaly, dysostosis multiplex,
vertebral deformities, mental retardation, and cherry-red spot/
myoclonus [3,5–7].
Auditory deﬁcits are common in patients with LSDs [8–10].
β-glucuronidase-deﬁcient mice, which serve as a model for the
LSD mucopolysaccharidosis VII (MPSVII) or Sly disease, have been
shown to have sensorineural defects in the inner ear as well as
conductive abnormalities in the middle and external ears, which
contribute to hearing loss [11,12]. Interestingly, although pro-
nounced lysosomal storage has been observed in many cell types
in the inner ear of MPSVII mice, no obvious loss of hair cells or
ganglion cells has been detected [11,12]. The molecular mechanism
of sensorineural hearing defects in this mouse model and in LSD
patients in general remains unclear.
Cochlear duct consists of three ﬂuid-ﬁlled compartments: the
scala vestibuli, the scala media, and the scala tympani. The scala
vestibuli and the scala tympani are ﬁlled with perilymph, a ﬂuid
whose ionic composition is similar to that of cerebrospinal ﬂuid
(reviewed in [13]). Endolymph is the ﬂuid within the scala
media, which is sealed by virtue of tight junctions between
adjacent cells including the sensory hair cells that line its
boundaries (reviewed in [13]). Many sensorineural defects in the
inner ear are related to the dysfunction of homeostasis of the
endolymph [14,15]. Endolymph contains high concentration of
potassium, which is pumped mainly by the stria vascularis, a
highly vascularized epithelium lining along the lateral part of scala
media (reviewed in [13]). The stria vascularis is composed of three
layers of cells: marginal cells, intermediate cells, and basal cells
(reviewed in [13]). The transport of potassium into the scala
media by the stria vascularis is against the ionic gradient and thus
builds up a high potassium concentration (approximate 160 mM)
and positive endolymphatic potential (EP, approximate 90 mV)
surrounding the scala media [16]. The pH value of endolymph is
maintained at 7.4 under physiological conditions [16]. Injection of
acetazolamide to scala media to acidify the endolymph caused
reduction of EP [17].
Neu1-knockout mice lack Neu1 activity and have been shown to
develop a severe sialidosis phenotype [18,19]. These mice exhibit
age-dependent extramedullary hematopoiesis caused by increased
lysosomal exocytosis in the bone niche, resulting from oversialyla-
tion of the lysosomal-associated membrane protein-1 (Lamp-1), a
primary player in this process [19]. In this study, we have
characterized the auditory defects in Neu1−/− mice, which display
a profound hearing loss as early as P21. We found that hearing loss
in Neu1−/− mice involves both conductive and sensorineural
components. The loss of Neu1 activity and its effect on Lamp-1,
which in turn exacerbates lysosomal exocytosis, provides a mech-
anism for how progressive hearing loss occurs in Neu1−/− mice. Our
studies in the Neu1 knockout mouse model put forward a molecular
mechanism that may contribute to hearing loss in NEU1 deﬁcient
patients and identify potential therapeutic targets for treatment of
this severe condition.
2. Results
2.1. Hearing loss in Neu1−/− mice
We examined the auditory function of Neu1−/−mice by analyzing
ABR thresholds at different ages. At P21, a signiﬁcant elevation in ABR
thresholds was recorded in null mice compared to wild-types, which
ranged from 48 to 55 dB for click, 8, 16, and 32 kHz tone stimuli,
respectively (Fig. 1A, B). Hearing loss appeared to be progressive as
ABR thresholds at all stimuli were signiﬁcantly higher in Neu1−/−
mice at age P60 (for click stimuli: Pb0.05, Student's t-test; for tone
stimuli; Pb0.001, two-way ANOVA) (Fig. 1A, B). However, there wereno signiﬁcant threshold elevations in Neu1+/−mice at all ages tested
(data not shown).
2.2. Morphologic changes in the external and middle ears of
Neu1−/− mice
To determine whether abnormalities in the middle and external
ears could cause hearing loss in Neu1−/− mice, we performed a
histologic analysis of H&E stained tissue sections from mice at age
P21 and P60. In contrast to wild-type mice, Neu1−/− mice accu-
mulated cerumen in the external ear canal at P21 (Fig. 2A and C, and
data not shown). Neu1−/− mice had a thickened mucosa lining the
middle ear surface of the tympanic bulla (Fig. 2C). Cells resembling
those present in a typical chronic inﬂammatory responses [12,20] had
invaded but not ﬁlled the tympanic cavity (Fig. 2D). The middle ear
ossicles were over-ossiﬁed and showed a darker H&E staining pattern
than that of wild-type littermates (Fig. 2C). At P60, abnormalities in
the external and middle ear had substantially progressed in Neu1−/−
mice. The mice displayed a thickened cerumen occlusion in the
external auditory canal in addition to severe otitis media (Fig. 2G).
The middle ear ossicles were completely encased in connective
tissue, which had been inﬁltrated with different types of chronic
inﬂammatory-appearing cells (Fig. 2H). In addition, sclerosis marked
by irregular-shaped lacunae surrounded by dark-blue bony ring was
Fig. 2. Hematoxylin and eosin (H&E) staining shows morphologic changes in the middle and external ear of P21 Neu1−/−mice. Arrows indicate a mild thickening of the middle ear
mucosa in (C) and an inﬁltration of ﬁbrocytes in the middle ear cavity (D, asterisk) in Neu1−/−mice. There was also an accumulation of cerumen occlusion in the external auditory
canal (G, #) and chronic inﬂammatory pathologic changes in the middle ear. Scale bars: A, C, E, G: 400 μm; B, D, F, H: 150 μm.
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These morphological abnormalities found in the ear of Neu1−/−
mice are consistent with previous reports of other LSD models
[11,12,20].2.3. Morphologic changes in cochleae of Neu1−/− mice
To investigate the potential involvement of inner ear sensory
epithelia in the hearing loss seen in Neu1−/− mice, we examined the
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(Fig. 3). Neu1 was most abundant in interdental cells, external sulcus
cells, and ganglion cells. Staining was low in marginal cells, inner and
outer pillar cells, Boettcher cells and faint in inner and outer hair cells
and some ﬁbrocytes in the spiral ligament.
At P9, P21, and P60, there were morphologic abnormalities in
multiple cell types in Neu1−/− cochleae. At P9, toluidine blue staining
of semi-thin plastic sections showed no obvious abnormality in the
Neu1−/− cochlea, except for slight vacuolization in marginal cells of
the stria vascularis (data not shown). However, by P21, vacuolization
was apparent in many cell types (Fig. 4B–F), with the most extensive
vacuolization in marginal cells and external sulcus cells. Moderate
vacuolization was observed in both endothelial and mesothelial cells
of Reissner's membrane, inner sulcus cells, Boettcher cells, outer hair
cells, type-IV ﬁbrocytes of spiral ligament, spiral prominence,
interdental cells, and mesothelial cells lining in the perilymphatic
side of the basilar membrane. Although wild-type ganglion cellsFig. 3.Neu1 expression pattern in the cochleae of wild-typemice. (A) Illustration of various im
ES, external sulcus cell; B, Boettcher cell; OHC, outer hair cell; OP, outer pillar cell; IP, inne
Membrane. Different cell types express Neu1 in scala media (B), organ of Corti (C), and cochle
only some background staining (D.F). Scale bar: 50 μm.expressed high levels of Neu1 (Fig. 3E), vacuolization was detectable
in Neu1−/− mice only at P60 but not P21 (Fig. 4E, and data not
shown). Glial cells did not show recognizable vacuolization. Interest-
ingly, there was no loss of hair cells or ganglion cells in Neu1−/−mice
at both P21 and P60.
Since the most prominent morphologic changes occurred in
marginal cells of the stria vascularis in Neu1−/− cochleae, morpho-
logic changes in these cells were further examined at the ultrastruc-
tural level (Fig. 5). As early as P9, numerous vesicles approached to or
docked at the apical surface of the marginal cells facing the scala
media. At P21, vacuolization of marginal cells caused distention of
these cells as well as a several fold increase in their size compared
with wild-type cells. At P21, appearance of stereocilia in cochleae of
Neu1−/− mice and wild-type littermates were similar under SEM
(data not shown), indicating that the morphologic integrity of the
mechanoelectrotransducer remained unchanged. The apical surface of
marginal cells in the stria vascularis of wild-type mice was smoothportant cell types in the cochlear scala media. Abbreviations in ﬁgure: M,marginal cell;
r pillar cell; IHC, inner hair cell; IS, inner sulcus cell; ID, interdental cell; R: Reissner's
ar ganglion from P21wild-typemice whereas correspondent Neu1−/− cochleae display
Fig. 4. Semi-thin plastic sections stained with toluidine blue show themorphologic changes in the inner ear of P21 Neu1−/−mice. Normal morphology of a P21 Neu1+/+ cochlea (A).
Vacuolization (arrows) is observed in many cell types, such as Reissner's membrane cells, interdental cells of spiral limbus (B), inner sulcus cell, outer hair cells, andmesothelial cells
lining in the perilymphatic side of the basilar membrane (C), Boettcher cells, external sulcus cells, type-IV ﬁbrocytes (D), andmarginal cells of the stria vascularis (F). Vacuolization is
most prominent in marginal cells of the stria vascularis. Vacuolization in spiral ganglia (arrowhead) and putative surrounding glial cells (asterisk) at P21 in Neu1−/− cochleae (E) is
not evident. Scale bars: A: 60 μm; B, C, D, E, F: 30 μm.
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showed many invaginations and cavities, indicative of excessive
exocytosis/endocytosis of vesicles into the endolymph (Fig. 6B, C).
2.4. Lysosomal membrane proteins in cochleae of Neu1−/− mice
The earliest morphologic changes detected in the cochlea of
Neu1−/− mice were the numerous vesicles approaching to and
docking at the apical surface of marginal cells in the stria vascularis
at P9–P21. We have previously shown that Lamp-1 is a natural
substrate for Neu1 and is involved in lysosomal exocytosis.
Hypersialylation of Lamp-1 in Neu1−/− macrophages and patients'
ﬁbroblasts has been shown to cause an increase in the number of
docked lysosomes at the plasma membrane [19]. We therefore
studied whether similar posttranslational modiﬁcations also occurred
in cells of the Neu1−/− cochleae. Western blot analysis of cochlear
lysates at P21 showed that there was a marked increase in theprotein levels of Lamp-1 (2.98 fold) and Lamp-2 (3.19 fold) (Fig. 7,
left panel). In contrast, no obvious increase (1.02 fold) was observed
in the expression of Lamp-3, but its molecular weight was slightly
higher than in cochleae of wild-type mice (Fig. 7, left panel). The
lysosomal membrane protein Limp II was slightly more abundant
(1.46 fold) in the knock-out lysate, while the lowest molecular
weight band detected in the wild-type was absent in the Neu1−/−
sample (Fig. 7, left panel). There was no overt difference in molecular
weights and expression levels of several lysosomal and plasma
membrane (PM) proton-pump and ion channel proteins (Na+-K+
ATPase B1 subunit, KCNQ1, TRPV5/6), but the V-ATPase subunit B1
was more abundant in cochlear lysates from Neu1−/− mice (2.35
fold) (Fig. 7, left panel; data not shown). V-ATPase is a major
lysosomal membrane protein that pump protons into the lysosomes
and maintains the acidic environment of lysosomes [21].
Immunohistochemical analysis of the stria vascularis from cochle-
ar sections of P21 mice (Fig. 7, right panel) corroborated the protein
Fig. 5. Neu1−/− mice show extensive vacuolization in marginal cells of the stria vascularis. (A) The darker-stained cell in the marginal cell of a P9 Neu1+/+ cochlea. The ﬂattened
basal cell is at the bottom and the lighter-stain intermediate cell is located in the middle portion of the stria vascularis. (B) Vacuolization (⁎) inmarginal cells of P9Neu1−/−mice. (C)
No vacuolization in marginal cells and basal cells in P21 Neu1+/+mice. (D) Vacuolization (⁎) is more extensive in marginal cells at P21 (D) than at P9 (B) in Neu1−/−mice, however
vacuolization is also observed in basal cells in P21 Neu1−/− mice (D). Abbreviations in ﬁgure: E, endolymph; M, marginal cell; I, intermediate cells; B, basal cell; C, capillary. Scale
bar: 2 μm.
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markedly at the apical membrane of marginal cells in the cochlea of
Neu1−/− mice compared with wild-type cells, consistent with an
increase in the number of lysosomes approaching to and docking at
the PM. LIMP II expression level was slightly higher in Neu1−/−mice.
As a control, we checked other membrane proteins (KCNQ1, Na+-K+
ATPase B1 subunit) in which no change would be expected. These
membrane proteins indeed showed no substantial differences in
expression levels or localization in the stria vascularis of Neu1−/− and
wild-type mice (Fig. 7, right panel; data not shown).
2.5. Measurement of EP
The presence of numerous vesicles at the apical membrane of the
marginal cells was a feature unique of the Neu1−/− cochlea. The
increase in hypersialylated Lamp-1 and -2 in these cells at the same
location suggested that these vesicles were PM-docked lysosomesFig. 6. Scanning electronic microscopy of the stria vascularis in P21 Neu1+/+ (A) and Neu
(C, arrowheads). Scale bar: 4 μm.[19]. Recently, we have shown that an increase in the sialylation and
quantity of Lamp-1 in several Neu1−/− cell types correlated with
enhanced lysosomal exocytosis [19]. Based on the accumulated
evidence, we postulated that such phenotype could also occur in the
Neu1−/− cochlea. Our prediction was that the excessive discharge of
acidic lysosomal content into the endolymphwould decrease both the
pH and the EP of the endolymph. Unfortunately, direct measurement
of pH in the endolymph is technically very difﬁcult and prone to
artifacts, because the total volume of endolymph is only approxi-
mately 0.19 μl per cochlea in the mouse [22]. However, we directly
measured the EP in the basal turn of Neu1−/− mice and control
littermates and found that the EP was signiﬁcantly lower (∼20mV) in
Neu1−/−mice at ages P31 and P44 compared to wild-type littermates
(Fig. 8). This decrease would, in turn, cause a reduction in the
electrical gradient across themechanoelectrotransduction channels of
hair cells and could contribute to the progressive hearing loss seen in
Neu1−/− mice.1−/− (B, C) mice. There are many invaginations on the surface of the stria vascularis
Fig. 7. Changes in lysosomal membrane proteins in Neu1−/− cochleae. Left panel shows immunoblot analyses of selected lysosomal membrane and plasma membrane proteins in
Neu1−/− and Neu1+/+ cochleae, as indicated. GAPDHwas used as a loading control. Right panel shows immunohistochemical analysis, which indicates changes in the expression of
proteins in the stria vascularis in P21 Neu1-/-mice similar to those seen on the immunoblot. There is a marked increase in the expression of Lamp-1 (A, B) and Lamp-2 (C, D) mainly
in the marginal cells of the stria vascularis. The dark-stained lysosomes inside the marginal cells are bubble shaped. Lamp-3 (E, F) is also present in the apical portion of marginal
cells, but there is no noticeable difference in its expression in Neu1+/+and Neu1−/−mice. LIMP II (G, H) is expressed in the stria vascularis and surrounding Type-I ﬁbrocytes which
is consistent with the immunoblot results. Its expression level is slightly higher in Neu1−/−mice. KCNQ1 (I, J) is expressed on the surface of the apical membrane of marginal cells.
Scale bar: 40 μm.
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The loss of Neu1 activity and its effect on Lamp-1 provides a
mechanism for the occurrence of the profound and progressive
hearing loss in Neu1−/− mice. Whether the same or a similar
pathologic mechanism(s) is responsible for hearing loss in mouse
models of seemingly unrelated LSDs and in patients with LSDs
remains to be studied. The sensory apparatus of the inner ear is well
suited for unraveling the pathologic mechanisms of hearing loss in
LSDs because of the sensitivity of in vivo hearing measurements
currently available, the enclosed nature of the cochlear compartment,
and the knowledge of molecular pathways involved in auditory signaltransduction. To date, hearing loss has been studied in only some
mouse models of LSD, but these have given little information about
potential molecular mechanisms [9,11,12,20,23–25]. Characterization
of abnormalities present in the external, middle, and inner ears of
Neu1−/− mice in our study provides for the ﬁrst time a molecular
mechanism by which the deﬁciency of a lysosomal hydrolase may
cause hearing loss.
Consistent with studies of other mouse models of LSDs
[9,11,12,20,23–25]; we have demonstrated that hearing loss in
Neu1−/− mice involves both conductive and sensorineural compo-
nents. In P60 mice, severe abnormalities in both the external and
middle ears indicated the existence of conductive hearing loss. In
Fig. 8. Changes in the endolymphatic potential (EP) in Neu1−/−mice at ages P31–P44.
The EP is 100.4±11.9 mV (n=7, mean±SEM) in Neu1+/+ mice but is 80.5±19.1 mV
(n=6, mean±SEM) in Neu1−/− mice (Pb0.05, Student's t-test).
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however, a signiﬁcant 48 –55 dB elevation of ABR thresholds were
already evident at this early age. This inconsistency between the
abnormalities in the external and middle ears and the amount of
hearing loss indicates that hearing impairment in Neu1−/− mice is
preceded by structural defects of sensorineural components.
Various cell types in the inner ear exhibited vacuolization in
Neu1−/− mice at P21. Similar to other LSD mouse models, vacuoli-
zation was mainly found in cell types that are responsible for the
ionic homeostasis of endolymph such as inner sulcus cell, external
sulcus cells, ﬁbrocytes of spiral ligament, cells of Reissner’s
membrane, and inter-dental cells [11,12,23–25]. However, the
early onset of drastic vacuolization in marginal cells of the stria
vascularis in Neu1−/− mice was a unique feature [11,12,20,23–25].
Interestingly, we did not ﬁnd any notable hair cell degeneration at
ages as old as P60 in Neu1−/− mice, although vacuolization was
visible in outer hair cells (OHCs). OHC degeneration has not been
detected in most LSD models except in the MPS I mice at 1 year of age
[11,12,23–25]. In the mouse models of Pompe's disease, OHC
vacuolization had no apparent effect on the hearing sensitivity [9].
Morphological change in OHC could also contribute to the hearing
deﬁcit in Neu1−/− mice.
Recent studies showed that only glial cells but not ganglion cells
accumulated vacuolization in inner ears of MPS VII and MPS III mouse
models whereas Asa−/− mice exhibited dramatic degeneration of
cochlear ganglia [11,24]. We also found vacuolization in ganglia in
Neu1−/− mice at P60. Although the expression level of Neu1 in the
ganglia is high in wild-type mice, spiral ganglion cells showed no
overt vacuolization in Neu1−/−mice at P21. Therefore, dysfunction of
ganglion cells might not be a major factor in the profound hearing loss
observed in Neu1−/− mice at P21.
Additionally, vacuolization in mesothelial cells lining the basilar
membrane could change the passive mechanical properties of
cochlear partition and thus affect hearing sensitivity, as proposed
from other LSD models [11,24,25].
Immunohistochemical analysis showed that Neu1 is expressed in
many cochlear cell types, which line the epithelial surface of the
cochlear endolymphatic compartment. These cells are important to
maintain homeostasis of water-ionic recycling of the cochlear ﬂuid
and production and maintenance of EP [13]. Therefore, the lack of
Neu1may inﬂuence endolymphatic compositions that ultimatelymay
lead to the dysfunction of mechanoelectrotransduction in sensory hair
cells. In the Neu1−/− cochlea at as early as P9 cytoplasmic
vacuolization was already visualized mainly in marginal cells of the
stria vascularis, which play crucial roles in maintaining endolym-
phatic compositions such as K+ concentration and EP [13]. Therefore,
the morphologic changes we detected in marginal cells of the inner
ear of Neu1−/−mice are probably the earliest, and they further trigger
subsequent alterations in inner ear endolymph.We have recently shown that the deﬁciency of Neu1 causes the
hypersialylation of Lamp-1 in bone marrow cells from Neu1−/− mice
and ﬁbroblasts from patients with sialidosis. This prolongs the half-
life of Lamp-1 and results in an increase in docked lysosomes at the
PM. The latter phenomenon is associated with abnormally high levels
of lysosomes that exocytose their luminal content into the extracel-
lular environment [19]. The numerous indentations and cavities
present on the surface of the marginal cells facing the scala media in
P21 Neu1−/− mice support the notion that active endocytosis or
exocytosis, or both, are exacerbated in defective marginal cells at this
early age. Furthermore, the marked increase of Lamp1- and -2 but not
of plasma membrane proteins (Na-K ATPase B1 subunit, TRPV5,
TRPV6 or KCNQ1) near the apical surface of marginal cells in cochleae
of Neu1−/− mice could be indicative of increased exocytosis of the
luminal content into the endolymph. The release of large amount of
hypersialylated lysosomal luminal content carrying negative charge
would subsequently decrease the voltage potential inside the
endolymph. Our hypothesis that this should result in a decrease in
EP in Neu1−/− endolymph was indeed conﬁrmed. However, this
relatively moderate change in EP may not be sufﬁcient to explain the
substantial elevation (48 –55 dB) of hearing threshold in the mutant
mice, given the average empirical rate of 1 dB/mV [26].
The extensive apical vacuolization in marginal cells of Neu1−/−
mice indicates that the hearing defect may be caused by acidic
lysosomal components released from interdental and marginal cells.
This would decrease the pH of the endolymph and eventually lead to
impaired transduction of hair cells. Recent studies have shown that
acidiﬁcation of the endolymph can provoke an increase in the calcium
concentration of the cochlear endolymph, causing a dysfunction in the
mechanoelectrotransduction channel of hair bundles [27], and such
defects could ultimately result in deafness in Neu1−/− mice.
The V-type ATPase B1 subunit is a major lysosomal membrane
protein that pumps protons into the lysosomes and maintains the
acidic environment [21]. In cochlea, V-ATPase is expressed in both
interdental cells and cells of stria vascularis [28]. The increase in the
expression of the V-ATPase B1 subunit in the cochleae of Neu1−/−
mice may increase the transport of protons into the lysosomes,
thereby increasing acidity. Mutations of the V-ATPase B1 subunit are
known to cause sensorineural hearing loss in humans [26,27], and
several V-ATPase B1 mutant mice also display a hearing phenotype
similar to Neu1−/− mice [28–30]. In contrast, V-ATPase B1 knockout
mice do not exhibit any hearing phenotypes [29]. It is likely that the
increase of V-ATPase B1 in Neu1−/− mice may represent an effective
gain of function of V-ATPase B1. The increased expression of V-type
ATPase B1 in the cochleae of Neu1−/− mice is likely a compensatory
effect to help maintain the intralysosomal acidity by increasing the
inﬂux of protons into lysosomes. Presumably, the large amount of
negatively charged hypersialylated Lamp-1, Lamp2, and other
unidentiﬁed targets of Neu1 would neutralize and potentially
exceed the increased positive charge of protons by V-ATPase and
convergently reduce the EP in Neu1−/− cochlea. Nevertheless, we
cannot rule out a potential direct correlation between increased
expression of V-ATPase B1 and hearing loss in Neu1−/− mice. This
hypothesis can be tested by studying whether double-deﬁcient V-
ATPase B1/Neu1 mice have less severe hearing phenotypes than
Neu1−/− mice do.
In conclusion, we have provided evidence that the lack of Neu1 and
the potential exacerbation of lysosomal exocytosis in the inner ear
play a role in the occurrence of hearing loss in Neu1−/− mice. Fig. 9
shows one of the crucial downstream cascades of events that
contribute to the hearing phenotype. At P21, both conductive and
neurosensory defects contribute to hearing loss in Neu1−/− mice.
However, morphological changes such as the accumulation of
cerumen in the external ear canal, thickened mucosa and inﬂamma-
tion in the middle ear are possibly sufﬁcient to affect the efﬁciency of
sound transfer. Second, vacuolization in outer hair cells could also
Fig. 9. Proposedmechanisms of hearing loss inNeu1−/−mice (seeDiscussion for details).
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vacuolization in other cell types that maintain ionic homeostasis of
endolymph could also affect the hearing. Finally, all lysosomal storage
in cochlear cells could also affect the passive mechanics of the basilar
membrane and thus lead to a hearing deﬁcit. At present, we cannot
exclude the possibility that other mechanisms are also contributing to
the loss of hearing in Neu1−/− mice, nor do we know whether the
same factors underlie similar phenotypic alteration in other LSD
animal models and patients. Nonetheless, the current ﬁndings set the
basis for understanding the cause of hearing loss in NEU1 deﬁciencies
and for developing therapeutic interventions that may prevent or
reverse this disease phenotype.
4. Materials and methods
4.1. Mouse genotyping
Neu1−/− mice were generated by targeted disruption of the Neu1
locus, as previous reported [18], and maintained in an FVB genetic
background. A PCR-based strategy was used to identify genotypes of
Neu1-knockout mice from genomic DNA. Age-matched Neu1−/− and
Neu1+/+ controls from either littermate or different litters were used.
All animal procedures were carried out in accordance with the US
Public Health Service Policy on the Humane Care and Use of
Laboratory Animals and were approved by the institutional animal
care and use committees of the St. Jude Children’s Research Hospital
and the Oregon Health Sciences University.
4.2. ABR recording
The ABR assaywas performed as described previously [31]. All data
were analyzed by two-way ANOVA or Student's t-test.
4.3. Electronic microscopy and preparation of samples
Tissues were brieﬂy washed in 0.1 M PBS, post-ﬁxed in 0.8%
osmium tetroxide/3% ferrocyanide in 0.1 M PBS for 2 h, and washed
with deionized distilled water. Tissues were then dehydrated by usinga series of ascending concentrations of ethanol and stained en bloc
with 2% uranyl acetate/100% ethanol under vacuum for 1 h at 60 °C,
embedded in Spurr's resin (Ted Pella, Redding, CA), and polymerized
for 2 days at 60 °C. Semi-thin sections (40 μm) were stained with 0.1%
toluidine blue and photographed under a light microscope. Ultra-thin
sections (50 nm) were cut with a diamond knife, counterstained, and
observed by transmission electron microscopy. For scanning electron
microscopy (SEM), whole mounts of cochlear half-turns were critical-
point dried, sputter-coated with platinum, and imaged with a Philips
ESEM XL30 (FEI company, Netherlands).
4.4. Preparation of parafﬁn sections and hematoxylin and eosin
(H&E) staining
Mice were intracardiacally perfused and ﬁxed with 4% parafor-
maldehyde. The inner ears were isolated, postﬁxed, and decalciﬁed
in 120 mM EDTA (pH 7.2). For immunostaining of parafﬁn sections,
the decalciﬁed inner ear was transferred to 70% ethanol, dehy-
drated through a series of increasing gradients of ethanol, para-
fﬁnized, and embedded. A Richard-Allan microtome (Richard-Allan
Scientiﬁc, Kalamazoo, MI) was used to cut 12 -μm-thick sections of
the inner ear. Parafﬁn sections were dehydrated by using xylene, a
series of decreasing gradients of ethanol, hematoxylin, ammuno
water, eosin, acidic alcohol, and an increasing gradient of ethanol,
and then dried in xylene. Finally, slidesweremounted andobserved by
light microscopy.
4.5. Immunohistochemical analysis
Immunostaining was performed on de-parafﬁnized sections.
Brieﬂy, slides were rinsed twice with 0.01 mM PBS, treated with
10 mM sodium citrate buffer (pH 6.0) at 85 °C for 15 min, blocked
with blocking solution for 30min at room temperature, and incubated
with the primary antibody overnight at 4 °C. Slides were then rinsed 5
times with PBS. Biotin-labeled secondary antibodies (Vector Lab., Inc.
Burlingame, CA) were added on the slides and incubated at room
temperature for 1 h. The avidin–biotin complex solution was
subsequently added and slides were rinsed. DAB (KPL, Gaithersburg,
MD) reactions were performed according to manufacturer's manual
and monitored by light microscopy until desired staining was
obtained.
4.6. Western blot analysis
Fresh cochleae isolated from mice were homogenized in lysis
buffer [50mM Tris–HCl (pH 7.5); 150 mMNaCl, 5 mM EDTA (pH 8.0);
1% NP40; 5% glycerol, 1 mM DTT, 1 mM PMSF, 1×Complete cocktail
(Rosch, Germany); 0.5 mM sodium vanadate, 10 mM NaF]. Lysates
were loaded together with 4× Nupage LDS loading buffer (Invitrogen,
Carlsbad, CA) and DTT (ﬁnal concentration 100 mM) to the samples
and incubated at 65 °C for 10 min and resolved on a 4–20% SDS-PAGE
gel. The protein was then transferred to a polyvinylidene ﬂuoride
(PVDF) membrane and probed with Neu1 antibody [32], LAMP1
(clone 1D4B, BD Biosciences, San Diego, CA), LAMP2 (M3/84, Santa
Cruz Biotechnology, Santa Cruz, CA), LAMP3 (H-193, Santa Cruz),
LIMPII (N-18, Santa Cruz,), v-ATPase B1 (N-19, Santa Cruz), Na-K
ATPase B1 (N-20, Santa Cruz), TRPV5 (CAT21-A, Alpha Diagnostic
International, San Antonio, Texas), TRPV6 (CAT11-A, Alpha Diagnostic
International), and KCNQ1 (H-130 and C-20, Santa Cruz) antibodies.
For each antibody, 2 to 4 independent experiments from two sets of
mice were used in western blot analysis. To ensure quantiﬁcation of
protein expression levels were within the linear range, we only chose
amoderate exposed ﬁlm from 4-5 different exposure time-points. The
intensities of each band was measured using an Alpha DigDoc 1000
(Alpha Innotech Corporation, CA), subtracted background, and
normalized to GAPDH.
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The animal was anesthetized intramuscularly with 120 mg/kg
ketamine and the animal's head was secured in a custom-made head
holder attached to a three-dimensional translation stage. A tracheot-
omy was performed to ensure free, natural breathing. Rectal
temperatures were maintained at 38±1 °C with a servo-regulated
heating blanket. The auditory bulla was opened and the round
windowmembranewas exposed by using a ventral surgical approach.
A glass microelectrode with a tip diameter of approximately 0.4 μm
ﬁlled with 300 mM KCl was inserted into the scala media through the
round window membrane and the basilar membrane. A silver/silver
chloride electrode in the soft tissue of the neck served as a reference.
The DC voltage between the glass electrode and the reference
electrode was ampliﬁed using a BMA-200 bioampliﬁer (CWE, Inc.,
Ardmore, PA) and displayed on a digital voltmeter. The baseline level
was established before the tip of the glass electrode penetrated the
basilar membrane. When the tip of the microelectrode was surround-
ing the scala media, indicated by a sudden voltage increase, a stable
DC voltage over 30 s was considered the EP. The recording was
conﬁrmed by demonstrating that the potential returned to approx-
imately 0 mV when the electrode tip was retracted to the scale
tympani. All data was analyzed by Student's t-test.
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